Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Concomitant Medication Effects on Immunotherapy Outcomes in Sarcoma: A Pooled Post Hoc Analysis of Seven Phase II Trials.

Cancer medicine·2026
Same author

Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma.

Journal for immunotherapy of cancer·2026
Same author

Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

NCCN Guidelines® Insights: Soft Tissue Sarcoma, Version 1.2025.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma.

Cancer research communications·2025
Same author

Association of early dexrazoxane with reduced cardiotoxicity risk in sarcoma patients treated with anthracycline chemotherapy.

The oncologist·2025
Same journal

When should the medical oncologist call the surgeon?

Current problems in cancer·2026
Same journal

Clinical impact of a single time-point protocol paired FDG-PET and radioactive iodine scan for comprehensive disease assessment in differentiated thyroid cancer.

Current problems in cancer·2026
Same journal

Patterns of care for older multiple myeloma patients in the U.S.: An analysis of the national cancer database.

Current problems in cancer·2026
Same journal

Too late to fall: Time to PSA nadir and early oncologic failure after cryotherapy and high-intensity focused ultrasound for localized prostate cancer.

Current problems in cancer·2026
Same journal

Artificial intelligence, omics, and biomarkers: Redefining lung cancer early detection.

Current problems in cancer·2026
Same journal

Outcomes for females versus males treated with eribulin mesylate for advanced urothelial carcinoma.

Current problems in cancer·2026
See all related articles

Related Experiment Video

Updated: May 11, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Emerging therapies for sarcoma.

Sujana Movva1

  • 1Department of Medical Oncology, Fox Chase Cancer Center, Temple Health, USA.

Current Problems in Cancer
|May 31, 2013
PubMed
Summary
This summary is machine-generated.

Soft tissue sarcomas (STS) are rare connective tissue tumors with poor overall survival (OS). Understanding the diverse subtypes of STS is crucial for developing effective therapies and improving patient outcomes.

More Related Videos

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

Related Experiment Videos

Last Updated: May 11, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Soft tissue sarcomas (STS) are a group of uncommon connective tissue tumors.
  • Despite recent improvements, the overall survival (OS) for advanced sarcomas remains less than two years.
  • The heterogeneity of STS, with numerous subtypes, complicates drug discovery and treatment strategies.

Purpose of the Study:

  • To highlight the importance of understanding the molecular diversity within STS subtypes.
  • To emphasize the need for identifying predictors of treatment response in this heterogeneous disease.
  • To underscore the significance of testing novel therapeutic agents for advanced sarcomas.

Main Methods:

  • Review of emerging data on molecular profiles of STS subtypes.
  • Analysis of treatment response variations across different STS entities.
  • Discussion of challenges in drug discovery for heterogeneous cancers.

Main Results:

  • Emerging data suggest each STS subtype may be a distinct entity.
  • Unique molecular profiles and therapeutic sensitivities exist among subtypes.
  • Heterogeneity poses significant challenges for clinical trials and drug development.

Conclusions:

  • Recognizing STS subtypes as distinct diseases is essential.
  • Tailoring therapies based on molecular profiles and response predictors is critical.
  • Further research into novel agents and predictive biomarkers is of utmost importance for improving outcomes in advanced STS.